In acute promyelocytic leukemia (APL) patients, tumor-activated ILC2s secreted IL-13 to induce M-MDSCs (CD33+CD14+HLA-DR-) and to support tumor growth, while ATRA treatment reversed the increase of ILC2-MDSCs in APL [53] (Table 3). This evidence concerns the gene CD14 and acute promyelocytic leukemia.